Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 1916

Next Previous
X
Search
Drug Profile

SHR 1916

Alternative Names: IL-2 derivative SHR-1916; PEG-IL-2; PEG-modified/site-mutated interleukin-2 SHR-1916; SHR-1916

Latest Information Update: 28 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (Parenteral, Injection)
  • 09 Feb 2024 Jiangsu HengRui Medicine terminated a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral) due to R&D strategy adjustment (NCT04842630)
  • 20 Apr 2021 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease) in China in April 2021 (NCT04842630),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top